Endometrial Cancer

Cancer Epidemiology and Prevention

Volumn , Issue , 2009, Pages

  Cook, Linda S ^a   Weiss, Noel S ^b   Doherty, Jennifer A ^c   Chen, Chu ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cancer epidemiology; Cancer prevention; Cancer risk; Endometrium; Women

Indexed keywords

EID: 84920163879     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1093/acprof:oso/9780195149616.003.0053     Document Type: Chapter

References (335)

1. Albrektsen G, Heuch I, Tretli S, Kvale G. 1995. Is the risk of cancer of the corpus uteri reduced by a recent pregnancy? A prospective study of 765,756 Norwegian women. Int J Cancer 61:485-490.
2. Anderson KE, Anderson E, Mink PJ, et al. 2001. Diabetes and endometrial cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 10:611-616.
3. Antunes CM, Strolley PD, Rosenshein NB, et al. 1979. Endometrial cancer and estrogen use. Report of a large case-control study. N Engl J Med 300:9-13.
4. Archer DF, Furst K, Tipping D, Dain M-P, Vandepol C, for the CombiPatch Study Group. 1999. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause. Obstet Gynecol 94:498-503.
5. Armstrong B, Doll R. 1975. Environmental factors and cancer incidence and mortality in different countries, with special reference to dietary practices. Int J Cancer 15:617-631.
6. Armstrong BK, Ray RM, Thomas DB. 1988. Endometrial cancer and combined oral contraceptives. The Who Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 17:263-269.
7. Ascherio A, Hennekens C, Willet WC, et al. 1996. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27:1065-1072.
8. Austin DF, Roe KM. 1982. The decreasing incidence of endometrial cancer: public health implications. Am J Public Health 72:65-68.
9. Austin H, Austin JM, Jr., Partridge EE, Hatch KD, Shingleton HM. 1991. Endometrial cancer, obesity, and body fat distribution. Cancer Res 51:568-572.
10. Austin H, Drews C, Partridge EE. 1993. A case-control study of endometrial cancer in relation to cigarette smoking, serum estrogen levels, and alcohol use. Am J Obstet Gynecol 169:1086-1091.
11. Baanders-van Halewyn EA, Blankenstein MA, Thijssen JH, de Ridder CM, de Waard F. 1996. A comparative study of risk factors for hyperplasia and cancer of the endometrium. Eur J Cancer Prev 5:105-112.
12. Barbone F, Austin H, Partridge EE. 1993. Diet and endometrial cancer: a case-control study. Am J Epidemiol 137:393-403.
13. Baron JA, Byers T, Greenberg ER, Cummings KM, Swanson M. 1986. Cigarette smoking in women with cancers of the breast and reproductive organs. J Natl Cancer Inst 77:677-680.
14. Benshushan A, Paltiel O, Brzezinski A, et al. 2001. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol 98:53-57.
15. Benshushan A, Paltiel O, Rojansky N, Brzezinski A, Laufer N. 2002. IUD use and the risk of endometrial cancer. Eur J Obstet Gynecol Reprod Biol 105:166-169.
16. Beral V, Hannaford P, Kay C. 1988. Oral contraceptive use and malignancies of the genital tract. Lancet 2:1331-1335.
17. Beresford SAA, Weiss NS, Voigt LF, McKnight B. 1997. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen in postmenopausal women. Lancet 349:458-461.
18. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, van Leeuwen EE. 2000. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 356:881-887.
19. Bernstein L, Deapen D, Cerhan JR, et al. 1999. Tamoxifen therapy for breast cancer and endometrial cancer risk. J Natl Cancer Inst 91:1654-1662.
20. Berstein LM, Imyanitov EN, Gamajunova VB, et al. 2002. CYP17 genetic polymorphism in endometrial cancer: are only steroids involved? Cancer Lett 180:47-53.
21. Berstein LM, Imyanitov EN, Suspitsin EN, et al. 2001. CYP19 gene polymorphism in endometrial cancer patients. J Cancer Res Clin Oncol 127:135-138.
22. Boss SM, Huster WJ, Neild JA, Glant MD, Eisenhut CC, Draper MW. 1997. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 177:1458-1464.
23. Brinton LA, Barrett RJ, Berman ML, Mortel R, Twiggs LB, Wilbanks GD. 1993a. Cigarette smoking and the risk of endometrial cancer. Am J Epidemiol 137:281-291.
24. Brinton LA, Berman ML, Mortel R, et al. 1992. Reproductive, menstrual, and medical risk factors for endometerial cancer: results from a case-control study. Am J Obstet Gynecol 167:1317-1325.
25. Brinton LA, Hoover RN, and The Endometrial Cancer Collaborative Group. 1993b. Estrogen replacement therapy and endometrial cancer risk: unresolved issues. Obstet Gynecol 81:265-271.
26. Brynhildsen J, Hammar M. 2002. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women. Menopause 9:137-144.
27. Buring JE, Bain CJ, Ehrmann RL. 1986. Conjugated estrogen use and risk of endometrial cancer. Am J Epidemiol 124:434-441.
28. Burke TW, Tortolero-Luna G, Malpica A, et al. 1996. Endometrial hyperplasia and endometrial cancer. Obstet Gynecol Clin North Am 23:411-456.
29. Castellsague X, Thompson WD, Dubrow R. 1993. Intra-uterine contraception and the risk of endometrial cancer. Int J Cancer 54:911-916.
30. Castellsague X, Thompson WD, Dubrow R. 1996. Tubal sterilization and the risk of endometrial cancer. Int J Cancer 65:607-612.
31. Cauley JA, Norton L, Lippman ME, et al. 2001. Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134.
32. Cerin A, Heldaas K, Moeller B, the Scandinavian LongCycle Study Group. 1996. Adverse endometrial effects of long-cycle estrogen and progestogen replacement therapy (letter). N Engl J Med 334:668-669.
33. Chamlian DL, Taylor HB. 1970. Endometrial hyperplasia in young women. Obstet Gynecol 36:659-666.
34. Chu J, Schweid AI, Weiss NS. 1982. Survival among women with endometrial cancer: a comparison of estrogen users and nonusers. Am J Obstet Gynecol 143:569-573.
35. Clisham PR, de Ziegler D, Lozano K, Judd HL. 1991. Comparison of continuous versus sequential estrogen and progestin therapy in postmenopausal women. Obstet Gynecol 77:241-246.
36. Collins J, Donner A, Allen LH, Adams O. 1980. Oestrogen use and survival in endometrial cancer. Lancet 2:961-964.
37. Cook LS, Weiss NS, Schwartz SM, et al. 1995. A population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 87:1359-1364.
38. Corson SL, Richart RM, Caubel P, Lim P. 1999. Effect of a unique constant-estrogen, pulsed-progestin hormone replacement therapy containing 17Bestradiol and norgestimate on endometrial histology. Int J Fertil 44:279-285.
39. Coulam CB, Annegers JF, Kranz JS. 1983. Chronic anovulation syndrome and associated neoplasia. Obstet Gynecol 61:403-407.
40. Coulter A, McPherson K, Vessey M. 1988. Do British women undergo too many or too few hysterectomies? Soc Sci Med 27:987-994.
41. Cushing KL, Weiss NS, Voigt LF, McKnight B, Beresford SA. 1998. Risk of endometrial cancer in relation to use of low-dose, unopposed estrogens. Obstet Gynecol 91:35-39.
42. Cutler BS, Forbes AP, Ingersoll FM, Scully RE. 1972. Endometrial carcinoma after stilbestrol therapy in gonadal dysgenesis. N Engl J Med 287:628-631.
43. Damon A. 1960. Host factors in cancer of the breast and uterine cervix and corpus. J Natl Cancer Inst 24:483-516.
44. Daniell HW. 1976. Osteoporosis of the slender smoker. Vertebral compression fractures and loss of metacarpal cortex in relation to postmenopausal cigarette smoking and lack of obesity. Arch Intern Med 136:298-304.
45. Davidson BJ, Gambone JC, Lagasse LD, et al. 1981. Free estradiol in postmenopausal women with and without endometrial cancer. J Clin Endocrinol Metab 52:404-408.
46. De Castro A, Gonzalez-Gancedo P. 1986. The effect of copper ions in vivo on specific hormonal endometrial receptors. Adv Contracept 2:399-404.
47. De Vivo I, Huggins GS, Hankinson SE, et al. 2002. A functional polymorphism in the promoter of the progesterone receptor gene associated with endometrial cancer risk. Proc Natl Acad Sci U S A 99:12263-12268.
48. Deligdisch L, Holinka CF. 1987. Endometrial carcinoma: two diseases? Cancer Detect Prev 10:237-246.
49. Dicker RC, Scally MJ, Greenspan JR, et al. 1982. Hysterectomy among women of reproductive age: trends in the United States, 1970-1978. JAMA 248:323-327.
50. Diddle AW. 1952. Granulosa and theca cell ovarian tumors: Prognosis. Cancer 5:215-228.
51. Division of Cancer Prevention and Control, National Cancer Institute. 1988. 1987 Annual Cancer Statistics Review: including cancer trends 1950-1985. NIH Publication No. 88-2789.
52. Dockerty MB, Lovelady SB, Foust GT, Jr. 1951. Carcinoma of the corpus uteri in young women. Am J Obstet Gynecol 61:966-981.
53. Doll R, Kinlen LJ, Skegg DC. 1976. Letter: Incidence of endometrical carcinoma. Br Med J 1:1071-1072.
54. Dosemeci M, Hayes RB, Vetter R, et al. 1993. Occupational physical activity, socioeconomic status, and risks of 15 cancer sites in Turkey. Cancer Causes Control 4:313-321.
55. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. 2002. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 17:2209-2213.
56. Edman CD, MacDonald PC. 1978. Effect of obesity on conversion of plasma androstenedione to estrone in ovulatory and anovulator young women. Am J Obstet Gynecol 130:456-461.
57. Elliott EA, Matanoski GM, Rosenshein NB, Grumbine FC, Diamond EL. 1990. Body fat patterning in women with endometrial cancer. Gynecol Oncol 39:253-258.
58. Elwood JM, Boyes DA. 1980. Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol 10:173-187.
59. Elwood JM, Cole P, Rothman KJ, Kaplan SD. 1977. Epidemiology of endometrial cancer. J Natl Cancer Inst 59:1055-1060.
60. Escobedo LG, Lee NC, Peterson HB, Wingo PA. 1991. Infertility-associated endometrial cancer risk may be limited to specific subgroups of infertile women. Obstet Gynecol 77:124-128.
61. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. 1997a. Germ line polymorphisms in cytochrome-P450 1A1 (C4887 CYP1A1) and methylenetetrahydrofolate reductase (MTHFR) genes and endometrial cancer susceptibility. Carcinogenesis 18:2307-2311.
62. Esteller M, Garcia A, Martinez-Palones JM, Xercavins J, Reventos J. 1997b. Susceptibility to endometrial cancer: influence of allelism at p53, glutathione S-transferase (GSTM1 and GSTT1) and cytochrome P-450 (CYP1A1) loci. Br J Cancer 75:1385-1388.
63. Ettinger B, Selby J, Citron JT, Vangessel A, Ettinger VM, Hendrickson MR. 1994. Cyclic hormone replacement therapy using quarterly progestin. Obstet Gynecol 83:693-700.
64. Ewertz M, Schou G, Boice JD. 1988. The joint effect of risk factors on endometrial cancer. Eur J Cancer Clin Oncol 24:189-194.
65. Farhi DC, Nosanchuk J, Silverberg SG. 1986. Endometrial adenocarcinoma in women under 25 years of age. Obstet Gynecol 68:741-745.
66. Feigelson HS, Coetzee GA, Kolonel LN, Ross RK, Henderson BE. 1997. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res 57:1063-1065.
67. Feigelson HS, McKean-Cowdin R, Coetzee GA, Stram DO, Kolonel LN, Henderson BE. 2001. Building a multigenic model of breast cancer susceptibility: CYP17 and HSD17B1 are two important candidates. Cancer Res 61:785-789.
68. Finkle WD, Greenland S, Miettinen OS, Ziel HK. 1995. Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control 6:99-102.
69. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. 1994. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Instit 86:27-37.
70. Fisher B, Costantino JP, Wickerham DL, et al. 1998. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 90:1371-1388.
71. Folsom AR, Kaye SA, Potter JD, Prineas RJ. 1989. Association on incident carcinoma of the endometrium with body weight and fat distribution in older women: early findings of the Iowa Women's Health Study. Cancer Res 49:6828-6831.
72. Food and Drug Administration. 1976. Estrogens and endometrial cancer. FDA Drug Bulletin 6:18-20.
73. Fornander T, Rutqvist LE, Cedermark B, et al. 1989. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1:117-120.
74. Franks AL, Kendrick JS, Tyler CW, Jr. 1987. Postmenopausal smoking, estrogen replacement therapy, and the risk of endometrial cancer. Am J Obstet Gynecol 156:20-23.
75. Friedman AJ, Ravnikar VA, Barbieri RL. 1987. Serum steroid hormone profiles in postmenopausal smokers and nonsmokers. Fertil Steril 47:398-401.
76. Gambrell RD, Massey FM, Castaneda TA, Ugenas AJ, Ricci CA. 1979. Reduced incidence of endometrial cancer among postmenopausal women treated with progestogens. J Am Geriatrics Soc XXVII:389-394.
77. Gapstur SM, Potter JD, Sellers TA, Kushi LH, Folsom AR. 1993. Alcohol consumption and postmenopausal endometrial cancer: results from the Iowa Women's Health Study. Cancer Causes Control 4:323-329.
78. Genant HK, Lucas J, Weiss S, et al. 1997. Low-Dose Esterified Estrogen Therapy. Arch Intern Med 157:2609-2615.
79. Goodman MT, Hankin JH, Wilkens LR, et al. 1997a. Diet, body size, physical activity, and the risk of endometrial cancer. Cancer Res 57:5077-5085.
80. Goodman MT, Wilkens LR, Hankin JH, Lyu LC, Wu AH, Kolonel LN. 1997b. Association of soy and fiber consumption with the risk of endometrial cancer. Am J Epidemiol 146:294-306.
81. Gordon J, Reagan JW, Finkle WD, Ziel HK. 1977. Estrogen and endometrial carcinoma. An independent pathology review supporting original risk estimate. N Engl J Med 297:570-571.
82. Gordon MD, Ireland K. 1994. Pathology of hyperplasia and carcinoma of the endometrium. Seminars Oncol 21:64-70.
83. Gorodeski GI, Beery R, Lunenfeld B, Geier A. 1992. Tamoxifen increases plasma estrogen-binding equivalents and has estradiol agonistic effect on histologically normal premenopausal and postmenopausal endometrium. Fert Steril 57:320-327.
84. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. 1995. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 85:304-313.
85. Grady D, Ernster VL. 1996. Endometrial cancer. In Schottenfeld D, Fraumeni JF, eds. Cancer Epidemiology and Prevention, 2nd edition. New York, Oxford University Press, pp. 1058-1089.
86. Gray LA, Christopherson WM, Hoover RN. 1997. Estrogens and endometrial carcinoma. Obstet Gynecol 49:385-389.
87. Green PK, Weiss NS, McKnight B, Voigt LF, Beresford SA. 1996. Risk of endometrial cancer following cessation of menopausal hormone use (Washington, United States). Cancer Causes Control 7:575-580.
88. Gruber JS, Luciani CT. 1986. Physicians changing postmenopausal sex hormone prescribing regimens. Prog Clin Biol Res 216:325-335.
89. Gruber SB, Thompson WD. 1996. A population-based study of endometrial cancer and familial risk in younger women. Cancer and Steroid Hormone Study Group. Cancer Epidemiol Biomarkers Prev 5:411-417.
90. Guillebraud J, Bonnar J, Morehead J, Matthews A. 1976. Menstrual blood-loss with intrauterine devices. Lancet 1:387-390.
91. Gusberg SB. 1947. Precursors of corpus carcinoma estrogens and adenomatous hyperplasia. Am J Obstet Gynecol 54:905-927.
92. Gusberg SB, Hall RE. 1961. Precursors of corpus cancer III. The appearance of cancer of the endometrium in estrogenically conditioned patients. Obstet Gynecol 17:397-412.
93. Gusberg SB, Kardon P. 1971. Proliferative endometrial response to thecagranulosa cell tumors. Am J Obstet Gynecol 111:633-643.
94. Hachisuga T, Fukuda K, Hirakawa T, Kawarabayashi T. 2001. The effect of nulliparity on survival in endometrial cancer at different ages. Gynecol Oncol 82:122-126.
95. Hachisuga T, Kaetsu A, Sugimori H, Kamura T, Tsuneyoshi M, Kawarabayashi T. 1998. Risk factors for endometrial cancer in Japanese women. Int J Gynecol Cancer 8:292-297.
96. Hachiya T, Kuriaki Y, Ueoka Y, Nishida J, Kato K, Wake N. 1999. WAF1 genotype and endometrial cancer susceptibility. Gynecol Oncol 72:187-192.
97. Haiman CA, Hankinson SE, Colditz GA, Hunter DJ, De Vivo I. 2001. A polymorphism in CYP17 and endometrial cancer risk. Cancer Res 61:3955-3960.
98. Hammond CB, Jelovsek FR, Lee KL, Creasman WT, Parker RT. 1979. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol 133:525-536.
99. Hannaford PC, Kay CR. 1998. The risk of serious illness among oral contraceptive users: evidence from the RCGP's oral contraceptive study. Br J Gen Pract 48:1657-1662.
100. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A. 1983. The epidemiology of endometrial cancer in young women. Br J Cancer 47:749-756.
101. Herrington LJ, Weiss NS. 1993. Postmenopausal unopposed estrogens: characteristics of use in relation to the risk of endometrial carcinoma. Annal Epidemiol 3:308-318.
102. Hill DA, Weiss NS, Beresford SA. 2000. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 183:1456-1461.
103. Hill DA, Weiss NS, Voigt LF, Beresford SA. 1997. Endometrial cancer in relation to intra-uterine device use. Int J Cancer 70:278-281.
104. Hinkula M, Pukkala E, Kyyronen P, Kauppila A. 2002. Grand multiparity and incidence of endometrial cancer: a population-based study in Finland. Int J Cancer 98:912-915.
105. Hirose K, Tajima K, Hamajima N, et al. 1999. Comparative case-referent study of risk factors among hormone-related female cancers in Japan. Jpn J Cancer Res 90:255-261.
106. Hirose K, Tajima K, Hamajima N, et al. 1996. Subsite (cervix/endometrium)-specific risk and protective factors in uterus cancer. Jpn J Cancer Res 87:1001-1009.
107. Hirvonen E, Salmi T, Puolakka J, et al. 1995. Can progestin be limited to very third month only in postmenopausal women taking eestrogen? Maturitas 21:39-44.
108. Hoogerland DL, Buchler DA, Crowley JJ, Carr WF. 1978. Estrogen use-risk of endometrial carcinoma. Gynecol Oncol 6:451-458.
109. Hoover R, Fraumeni JF, Everson R, Myers MH. 1976. Cancer of the uterine corpus after hormonal treatment for breast cancer. Lancet 1:885-887.
110. Horwitz RI, Feinstein AR. 1978. Alternative analytic methods for case-control studies of estrogens and endometrial cancer. N Engl J Med 299:1089-1094.
111. Howe HL. 1984. Age-specific hysterectomy and oophorectomy prevalence rates and the risks for cancer of the reproductive system. Am J Public Health 74:560-563.
112. Hulka BS, Chambless LE, Kaufman DG, Fowler WC, Greenberg BG. 1982. Protection against endometrial carcinoma by combination-product oral contraceptives. JAMA 247:475-477.
113. Hulka BS, Fowler WC, Kaufman DG, et al. 1980. Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol 137:92-101.
114. Hulley S, Furberg C, Barrett-Connor E, et al. 2002. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). JAMA 288:58-66.
115. Inoue M, Okayama A, Fujita M, Enomoto T, Tanizawa O, Ueshima H. 1994. A case-control study on risk factors for uterine endometrial cancer in Japan. Jpn J Cancer Res 85:346-350.
116. International Agency for Research on Cancer, World Health Organization. 1997. Biennial Report 1996/1997.
117. Jain MG, Howe GR, Rohan TE. 2000a. Nutritional factors and endometrial cancer in Ontario, Canada. Cancer Control 7:288-296.
118. Jain MG, Rohan TE, Howe GR. 2000b. Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 53:385-391.
119. Jain MG, Rohan TE, Howe GR, Miller AB. 2000c. A cohort study of nutritional factors and endometrial cancer. Eur J Epidemiol 16:899-905.
120. Jelovsek FR, Hammond CB, Woodard BH, et al. 1980. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol 137:85-91.
121. Jensen J, Christiansen C, Rodbro P. 1985. Cigarette smoking, serum estrogens, and bone loss during hormone-replacement therapy early after menopause. N Engl J Med 313:973-975.
122. Jick H, Walker AM, Rothman KJ. 1980. The epidemic of endometrial cancer: a commentary. Am J Public Health 70:264-267.
123. Jick H, Watkins RN, Hunter JR, et al. 1979. Replacement estrogens and endometrial cancer. N Engl J Med 300:218-222.
124. Jick SS, Walker AM, Jick H. 1993a. Estrogens, progesterone, and endometrial cancer. Epidemiol 4:20-24.
125. Jick SS, Walker AM, Jick H. 1933b. Oral contraceptives and endometrial cancer. Obstet Gynecol 82:931-935.
126. Jordan VC. 1995. Tamoxifen: toxicities and drug resistance during the treatment and prevention of breast cancer. Annual Rev Pharmacol Toxicol 35:195-211.
127. Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. 1996. A casecontrol study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncol 53:354-359.
128. Kasum CM, Nicodemus K, Harnack LJ, Jacobs DR, Jr., Folsom AR. 2001. Whole grain intake and incident endometrial cancer: the Iowa Women's Health Study. Nutr Cancer 39:180-186.
129. Kaufman DW, Shapiro S, Slone D, et al. 1980a. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 303:1045-1047.
130. Kaufman DW, Slone D, Rosenberg L, Miettinen OS, Shapiro S. 1980b. Cigarette smoking and age at natural menopause. Am J Public Health 70:420-422.
131. Kaufman RH, Reeves KO, Dougherty CM. 1976. Severe atypical endometrial changes and sequential contraceptive use. JAMA 236:923-926.
132. Kaye SA, Folsom AR, Soler JT, Prineas RJ, Potter JD. 1991. Associations of body mass and fat distribution with sex hormone concentrations in postmenopausal women. Int J Epidemiol 20:151-156.
133. Kelsey JL, LiVolsi VA, Holford TR, et al. 1982. A case-control study of cancer of the endometrium. Am J Epidemiol 116:333-342.
134. Kennedy DL, Baum C, Forbes MB. 1985. Noncontraceptive estrogens and progestins: use patterns over time. Obstet Gynecol 65:441-446.
135. Keshavarz H, Hillis SD, Kieke BA, Marchbanks PA. 2002. Hysterectomy Surveillance-United States, 1994-1999. MMWR CDC Surveill Summ 51:1-8.
136. Kessler II. 1970. Cancer mortality among diabetics. J Natl Cancer Inst 44:673-680.
137. Key TJ, Pike MC, Brown JB, Hermon C, Allen DS, Wang DY. 1996. Cigarette smoking and urinary oestrogen excretion in premenopausal and postmenopausal women. Br J Cancer 74:1313-1316.
138. King RJB, Whitehead MI. 1983. Estrogen and progestin effects on epithelium and stroma from pre-and postmenopausal endometria: application to clinical studies of the climacteric syndrome. In Jasonni VM, ed. Steroids and Endometrial Cancer. New York Raven Press.
139. Kirschner MA, Samjlik E, Drejka M, Szmal E, Schneider G, Ertel N. 1990. Androgenestrogen metabolism in women with upper body vs lower body obesity. J Clin Endocrinol Metab 70:473-479.
140. Kistner RW. 1973. Endometrial alterations associated with estrogen and estrogen-progestin combinations. In Norris HJ, Hertig AT, Abell MR, eds. The Uterus. Baltimore, Williams & Wilkins, pp. 227-254.
141. Kodama S, Kase H, Tanaka K, Matsui K. 1996. Multivariate analysis of prognostic factors in patients with endometrial cancer. Int J Gynaecol Obstet 53:23-30.
142. Koepsell TD, Weiss NS, Thompson DJ, Martin DP. 1980. Prevalence of prior hysterectomy in the Seattle-Tacoma area. Am J Public Health 70:40-47.
143. Koumantaki Y, Tzonou A, Koumantakis E, Kaklamani E, Aravantinos D, Trichopoulos D. 1989. A case-control study of cancer of endometrium in Athens. Int J Cancer 43:795-799.
144. Kurman RJ, Felix J, Archer DF, Nanavati N, Arce J-C, Moyer DL. 2000. Norethinedrone acetate and estradiol-induced endometrial hyperplasia. Obstet Gynecol 96:373-379.
145. Kurman RJ, Kaminski PF, Norris HJ. 1985. The behavior of endometrial hyperplasia. A long-term study of "untreated" hyperplasia in 170 patients. Cancer 56:403-412.
146. Kvale G, Heuch I, Ursin G. 1988. Reporductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 8:6217-6221.
147. La Vecchia C, Decarli A, Fasoli M, et al. 1986a. Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 54:311-317.
148. La Vecchia C, Decarli A, Fasoli M, Gentile A. 1986b. Nutrition and diet in the etiology of endometrial cancer. Cancer 57:1248-1253.
149. La Vecchia C, Franceschi S, Decarli A. 1984. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 73:667-671.
150. La Vecchia C, Negri E, Franceschi S, D'Avanzo B, Boyle P. 1994. A case-control study of diabetes mellitus and cancer risk. Br J Cancer 70:950-953.
151. Lacey JV, Jr., Brinto LA, Mortel R, et al. 2000. Tubal sterilization and risk of cancer of the endometrium. Gynecol Oncol 79:482-484.
152. Lambe M, Wuu J, Weiderpass E, Hsieh CC. 1999. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 10:43-49.
153. Larson JA. 1954. Estrogens and endometrial cancer. Obstet Gynecol 3:551-572.
154. Lawrence C, Tessaro I, Durgerian S, et al. 1987. Smoking, body weight, and early-stage endometrial cancer. Cancer 59:1665-1669.
155. Le Marchand L, Wilkens LR, Mi M-P. 1991. Early-age body size, adult weight gain and endometrial cancer risk. Int J Cancer 48:807-811.
156. Lesko SM, Rosenberg L, Kaufman DW, et al. 1985. Cigarette smoking and the risk of endometrial cancer. N Engl J Med 313:593-596.
157. Lesko SM, Rosenberg L, Kaufman DW, et al. 1991. Endometrial cancer and age at last delivery: evidence for an association. Am J Epidemiol 133:554-559.
158. Levi F, Franceschi S, Negri E, La Vecchia C. 1993a. Dietary factors and the risk of endometrial cancer. Cancer 71:3575-3581.
159. Levi F, La Vecchia C, Gulie C, Franceschi S, Negri E. 1993b. Oestrogen replacement treatment and the risk of endometrial cancer: an assessment of the role of covariates. Eur J Cancer 29A: 1445-1449.
160. Levi F, La Vecchia C, Gulie C, et al. 1991. Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control 2:99-103.
161. Levi F, La Vecchia C, Negri E, Franceschi S. 1993c. Selected physical activities and the risk of endometrial cancer. Br J Cancer 67:846-851.
162. Liang AP, Levenson AG, Layde PM, et al. 1983. Risk of breast, uterine corpus, and ovarian cancer in women receiving medroxyprogesterone injections. JAMA 249:2909-2912.
163. Littman AJ, Beresford SA, White E. 2001a. The association of dietary fat and plant foods with endometrial cancer (United States). Cancer Causes Control 12:691-702.
164. Littman AJ, Voigt LF, Beresford SA, Weiss NS. 2001b. Recreational physical activity and endometrial cancer risk. Am J Epidemiol 154:924-933.
165. Lochen ML, Lund E. 1997. Childbearing and mortality from cancer of the corpus uteri. Acta Obstet Gynecol Scand 76:373-377.
166. Lucas WE. 1974. Causal relationships between endocrine-metabolic variables in patients with endometrial carcinoma. Obstet Gynecol Surv 29:507-528.
167. Lyon FA, Frisch MJ. 1976. Endometrial abnormalities occurring in young women on longterm sequential oral contraceptives. Obstet Gynecol 47:639-643.
168. Lyon JL, Gardner JW. 1977. The rising frequency of hysterectomy: its effect on uterine cancer rates. Am J Epidemiol 105:439-443.
169. Maatela J, Aromaa A, Salmi T, Pohja M, Vuento M, Gronroos M. 1994. The risk of endometrial cancer in diabetic and hypertensive patients: a nationwide record-linkage study in Finland. Annales Chirurgiae et Gynaecologiae-Supplementum 208:20-24.
170. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. 1978. Effect of obesity on conversion of plasma androstenedione to estrone in postmenopausal women with and without endometrial cancer. Am J Obstet Gynecol 130:448-455.
171. MacDonald PC, Siiteri PK. 1974. The relationship between the extraglandular production of estrone and the occurrence of endometrial neoplasia. Gynecol Oncol 2:259-263.
172. Mack TM, Pike MC, Henderson BE, et al. 1976. Estrogens and endometrial cancer in a retirement community. N Engl J Med 294:1262-1267.
173. Magos AL, Brincat M, Studd JW, Wardle P, Schlesinger P, O'Dowd T. 1985. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 65:496-499.
174. Mant JW, Vessey MP. 1994. Ovarian and endometrial cancers. In Cancer Surveys Volume 19: Trends in Cancer Incidence and Mortality. Imperial Cancer Research Fund. London, pp. 287-307.
175. Marra G, Boland CR. 1995. Hereditary nonpolyposis colorectal cancer: the syndrome, the genes, and historical perspectives. J Natl Cancer Inst 87:1114-11125.
176. Marrett LD, Elwood JM, Meigs JW, et al. 1978. Recent trends in the incidence and mortality of cancer of the uterine corpus in Connecticut. Gynecol Oncol 6:183-195.
177. Mattsson LA, Samsioe G. 1985. Estrogen-progestogen replacement in climacteric women, particularly as regards a new type of continuous regimen. Acta Obstet Gynecol Scand Suppl 130:53-58.
178. McCann SE, Freudenheim JL, Marshall JR, Brasure JR, Swanson MK, Graham S. 2000. Diet in the epidemiology of endometrial cancer in western New York (United States). Cancer Causes Control 11:965-974.
179. McDonald TW, Annegers JF, O'Fallon WM, Dockerty MB, Malkasian GD, Kurland LT. 1977. Exogenous estrogen and endometrial carcinoma: case-control and incidence study. Am J Obstet Gynecol 127:572-580.
180. McKean-Cowdin R, Feigelson HS, Pike MC, Coetzee GA, Kolonel LN, Henderson BE. 2001. Risk of endometrial cancer and estrogen replacement therapy history by CYP17 genotype. Cancer Res 61:848-849.
181. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. 1996. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 143:1195-1202.
182. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. 1986. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. N Engl J Med 315:1305-1309.
183. Modan B, Ron E, Lerner-Geva L, et al. 1998. Cancer incidence in a cohort of infertile women. Am J Epidemiol 147:1038-1042.
184. Mogren I, Stenlund H, Hogberg U. 2001. Long-term impact of reproductive factors on the risk of cervical, endometrial, ovarian and breast cancer. Acta Oncol 40:849-854.
185. Moradi T, Weiderpass E, Signorello LB, Persson I, Nyren O, Adami HO. 2000. Physical activity and postmenopausal endometrial cancer risk (Sweden). Cancer Causes Control 11:829-837.
186. Moyer DL, Mishell DR. 1971. Reactions of human endometrium to the intrauterine foreign body. II. Long-term effects on the endometrial histology and cytology. Am J Obstet Gynecol 111:66-80.
187. Muir C, Waterhouse J, Mack T, Powell J, Whelan S. 1987. Cancer Incidence in Five Continents (Vol 5). IARC, Lyon, France.
188. Nachtigall LE, Nachtigall RH, Nachtigall RD. 1979. Estrogen replacement therapy. II. A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 54:74-79.
189. Nagamani M, Stuart CA. 1998. Specific binding and growth-promoting activity of insulin in endometrial cancer cells in culture. Am J Obstet Gynecol 179:6-12.
190. Newcomb PA, Trentham-Dietz A. 2000. Breast feeding practices in relation to endometrial cancer risk, USA. Cancer Causes Control 11:663-667.
191. Newcomb PA, Trentham-Dietz A, Storer BE. 1997. Alcohol consumption in relation to endometrial cancer risk. Cancer Epidemiol Biomarkers Prevent 6:775-778.
192. Newcomer LM, Newcomb PA, Trentham-Dietz A, Storer BE. 2001. Hormonal risk factors for endometrial cancer: modification by cigarette smoking (United States). Cancer Causes Control 12:829-835.
193. Nishioka Y, Kobayashi K, Sagae S, et al. 2000. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res 91:612-615.
194. Nyholm HC, Nielsen AL, Lyndrup J, Dreisler A, Hagen C, Haug E. 1993. Plasma oestrogens in postmenopausal women with endometrial cancer. Br J Obstet Gynaecol 100:1115-1119.
195. O'Mara BA, Byers T, Schoenfeld E. 1985. diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 38:435-441.
196. Olson JE, Sellers TA, Anderson KE, Folsom AR. 1999a. Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? A prospective cohort study and a nested case-control family study of older women. Cancer 85:2444-2449.
197. Olsen SH, Elahi A, Roy P, Berwick M. 1999b. CYP17 and COMT genotypes in endometrial cancer (abstract #26). Am J Epidemiol 149: SER Abstracts S7, p. 57.
198. Olson SH, Elahi A, Tang G, et al. 2000. Polymorphisms in CYP1A1 and CYP1B1 in endometrial cancer (abstract #149). Proc Am Assoc Cancer Res 41:23-23.
199. Olson SH, Trevisan M, Marshall JR, et al. 1995. Body mass index, weight gain, and risk of endometrial cancer. Nutr Cancer 23:141-149.
200. Olson SH, Vena JE, Dorn JP, et al. 1997. Exercise, occupational activity, and risk of endometrial cancer. Ann Epidemiol 7:46-53.
201. Paganini-Hill A, Ross RK, Henderson BE. 1989. Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 59:445-447.
202. Parazzini F, La Vecchia C, D'Avanzo B, Moroni S, Chatenoud L, Ricci E. 1995a. Alcohol and endometrial cancer risk: findings from an Italian case-control study. Nutrit Cancer 23:55-62.
203. Parazzini F, La Vecchia C, Moroni S. 1994a. Intrauterine device use and risk of endometrial cancer. Br J Cancer 70:672-673.
204. Parazzini F, La Vecchia C, Moroni S, Chatenoud L, Ricci E. 1994b. Family history and the risk of endometrial cancer. Int J Cancer 59:460-462.
205. Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. 1991. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 164:522-527.
206. Parazzini F, La Vecchia C, Negri E, Moroni S, Chatenoud L. 1995b. Smoking and risk of endometrial cancer: results from an Italian case-control study. Gynecol Oncol 56:195-199.
207. Parazzini F, La Vecchia C, Negri E, et al. 1999. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 81:539-542.
208. Parazzini F, Negri E, La Vecchia C, et al. 1998. Role of reproductive factors on the risk of endometrial cancer. Int J Cancer 76:784-786.
209. Parkin DM, Muir C, Whelan S, Gao Y-T, Ferlay J, Powell J. 1992. Cancer Incidence in Five Continents (Vol. 6). IARC, Lyon, France.
210. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J. 1997. Cancer Incidence in Five Continents. Volume VII IARC, Lyon, France.
211. Parslov M, Lidegaard O, Klintorp S, et al. 2000. Risk factors among young women with endometrial cancer: a Danish case-control study. Am J Obstet Gynecol 182:23-29.
212. Paterson ME, Wade-Evans T, Sturdee DW, Thom MH, Studd JW. 1980. Endometrial disease after treatment with oestrogens and progestogens in the climacteric. Br Med J 280:822-824.
213. PDR. 2003. Physicians' Desk Reference, 57th ed. Montvale, New Jersey.
214. Peller S, Halperin R, Schneider D, Kopilova Y, Rotter V. 1999. Polymorphisms of the p53 gene in women with overian or endometrial carcinoma. Oncol Rep 6:193-197.
215. Persson I, Adami H, Bergkvist L, et al. 1989. Risk of endometrial cancer after treatment with oestrogens alone or in conjunction with progestogens: results of a prospective study. Br Med J 298:147-151.
216. Persson I, Weiderpass E, Bergkvist L, Bergstrom R, Schairer C. 1999. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control 10:253-260.
217. Petridou E, Belechri M, Dessypris N, et al. 2002a. Leptin and body mass index in relation to endometrial cancer risk. Ann Nutr Metab 46:147-151.
218. Petridou E, Koukoulomatis P, Dessypris N, Karalis D, Michalas S, Trichopoulos D. 2002b. Why is endometrial cancer less common in Greece than in other European Union countries? Eur J Cancer Prev 11:427-432.
219. Pettersson B, Adami HO, Bergstrom R. 1985a. Obesity, hypertension and diabetes as risk factors for endometrial cancer. In Risk Factors for Endometrial Carcinoma. Uppsala, Sweden, Acta Universitatis Upsaliensis. Comprehensive Summaries of Upsala Dissertations from the Faculty of Medicine, Vol 6, 42 pages.
220. Pettersson B, Adami HO, Bergstrom R, Johansson ED. 1986a. Menstruation span-a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand 65:247-255.
221. Pettersson B, Adami HO, Lindgren a, Hesselius I. 1985b. Endometrial polyps and hyperplasia as risk factors for endometrial carcinoma. A case-control study of curettage specimens. Acta Obstet Gynecol Scand 64:653-659.
222. Pettersson B, Adami HO, Persson I, Bergstrom R, Lindgren A, Johansson ED. 1986b. Climacteric symptoms and estrogen replacement therapy in women with endometrial carcinoma. Acta Obstet Gynecol Scand 65:81-87.
223. Pickar JH, Yeh I-T, Wheeler JE, Cunnane MF, Speroff L. 2001. Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 76:25-31.
224. Pike MC, Peters RK, Cozen W, et al. 1997. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Instit 89:1110-1116.
225. Pisani P, Parkin DM, Bray F, Ferlay J. 1999. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 83:18-29.
226. Pitot HC. 1986. Fundamentals of Oncology. New York, Marcel Dekker Inc.
227. Potischman N, Swanson CA, Brinton La, et al. 1993. Dietary associations in a case-control study of endometrial cancer. Cancer Causes Control 4:239-250.
228. Pukkala E, Kyyronen P, Sankila R, Holli K. 2002. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based casecontrol study. Int J Cancer 100:337-341.
229. Pukkala E, Poskiparta M, Apter D, Vihko V. 1993. Life-long physical activity and cancer risk among Finnish female teachers. Eur J Cancer Prev 2:369-376.
230. Pukkala E, Tulenheimo-Silfvast A, Leminen A. 2001. Incidence of cancer among women using long versus monthly cycle hormonal replacement therapy, Finland 1994-1997. Cancer Causes Control 12:111-115.
231. Ragozzino M, Melton LJ, Chu CP, Palumbo PJ. 1982. Subsequent cancer risk in the incidence cohort of Rochester, Minnesota, residents with diabetes mellitus. J Chronic Dis 35:13-19.
232. Ribeiro G, Swindell R. 1992. The Christie Hospital Adjuvant Tamoxifen Trial. J Natl Cancer Instit 11:121-125.
233. SEER (Surveillance, Epidemiology, and End Results) Program () Public-Use Data (1973-1999), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2002, based on the November 2001 submission.
234. Robboy SJ, Bradley R. 1979. Changing trends and prognostic features in endometrial cancer associated with exogenous estrogen therapy. Obstet Gynecol 54:269-277.
235. Rosenblatt KA, Thomas DB. 1995. Prolonged lactation and endometrial cancer. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 24:499-503.
236. Rosenblatt KA, Thomas DB, The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. 1991. Hormonal content of combined oral contraceptives in relation to the reduced risk of endometrial cancer. Int J Cancer 49:870-874.
237. Rosenblatt KA, Thomas DB, WHO Collaborative Study of Neoplasia and Steroid Contraception. 1996. Intrauterine devices and endometrial cancer. Contraception 54:329-332.
238. Ross RK, Paganini-Hill A, Roy S, Chao A, Henderson BE. 1988. Past and present preferred prescribing practices of hormone replacement therapy among Los Angeles gynecologists: possible implications for public health. Am J Public Health 78:516-519.
239. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S. 1990. Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 162:148-154.
240. Ruddon RW. 1995. Cancer Biology, 3rd ed. New York, Oxford University Press, pp. 240-251.
241. Rutanen EM, Stenman S, Blum W, Karkkainen T, Lehtovirta P, Stenman UH. 1993. Relationship between carbohydrate metabolism and serum insulin-like growth factor system in postmenopausal women: comparison of endometrial cancer patients with healthy controls. J Clin Endocrinol Metab 77:199-204.
242. Salazer-Martinez E, Lazcano-Ponce EC, Gonzalez Lira-Lira G, Escudero-De los Rios P, Salmeron-Castro J, Hernandez-Avila M. 1999. Reproductive factors of ovarian and endometrial cancer risk in a high fertility population in Mexico. Cancer Res 59:3658-3662.
243. Salazar-Martinez E, Lazcano-Ponce EC, Lira-Lira GG, et al. 2000. Case-control study of diabetes, obesity, physical activity and risk of endometrial cancer among Mexican women. Cancer Causes Control 11:707-711.
244. Salerno LJ. 1962. Feminizing mesenchymomas of the ovary-An analysis of 28 granulosatheca cell tumors and their relationship to coexistent carcinoma. Am J Obstet Gynecol 84:731-738.
245. Salvesen HB, Akslen LA, Albrektsen G, Iversen OE. 1998. Poorer survival of nulliparous women with endometrial carcinoma. Cancer 82:1328-1333.
246. Sasaki M, Sakuragi N, Dahiya R. 2003. The CAG repeats in exon 1 of the androgen receptor gene are significantly longer in endometrial cancer patients. Biochem Biophysical Res Comm 35:1105-1108.
247. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. 2002. Polymorphisms of estrogen receptor alpha gene in endometrial cancer. Biochem Biophys Res Commun 297:558.
248. Sasco AJ, Chaplin G, Amoros E, Saez S. 1996. Endometrial cancer following breast cancer: effect of tamoxifen and castration by radiotherapy. Epidemiol 7:9-13.
249. Satyaswaroop PG, Zaino RJ, Mortel R. 1984. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res 44:4006-4010.
250. Schapira DV, Kumar RD, Lyman GH, Cavanagh D, Roberts WS, LaPolla J. 1991. Upper-Body Fat Distribution and Endometrial Cancer Risk. JAMA 266:1808-1811.
251. Schiff I, Sela HK, Cramer D, Tulchinsky D, Ryan KJ. 1982. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 37:79-82.
252. Shapiro JA, Weiss NS, Beresford SA, Voigt LF. 1998. Menopausal hormone use and endometrial cancer, by tumor grade and invasion. Epidemiol 9:99-101.
253. Shapiro S, Kaufman DW, Slone D, et al. 1980. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 303:485-489.
254. Shapiro S, Kelly JP, Rosenberg L, et al. 1985. Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 313:969-972.
255. Sharp L, Cardy AH, Cotton SC, Little J. 2004. CYP17 gene polymorphisms: prevalence and associations with hormone levels and related factors. A Huge review. Amer J Epidemiol 160:729-740.
256. Shaw ST, Macaulay LK. 1979. Morphorlogic studies on IUD-induced metrorrhagia. II. Surface changes of the endometrium and microscopic localization of bleeding sites. Contraception 19:63-81.
257. Sherman BM, Korenman SG. 1974. Measurement of serum LH, FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 39:145-149.
258. Shields TS, Weiss NS, Voigt LF, Beresford SA. 1999. The additional risk of endometrial cancer associated with unopposed estrogen use in women with other risk factors. Epidemiology 10:733-738.
259. Shoff SM, Newcomb PA. 1998. Diabetes, body size, and risk of endometrial cancer. Am J Epidemiol 148:234-240.
260. Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF, Jr. 1991. A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 49:38-43.
261. Shu XO, Brinton LA, Zheng W, et al. 1992. Relation of obesity and body fat distribution to endometrial cancer in Shanghai, China. Cancer Res 52:3865-3870.
262. Shu XO, Hatch MC, Zheng W, Gao YT, Brinton LA. 1993a. Physical activity and risk of endometrial cancer. Epidemiol 4:342-349.
263. Shu XO, Zheng W, Potischman N, et al. 1993b. A population-based case-control study of dietary factors and endometrial cancer in Shanghai, People's Republic of China. Am J Epidemiol 137:155-165.
264. Shulman LP, Yankov V, Uhl K. 2002. Safety and efficacy of a continuous oncea-week 17B-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. Menopause 9:195-207.
265. Siiteri PK, MacDonald PC. 1973. The role of extra-glandular estrogen in human endocrinology. Handbook of Physiology 2:615.
266. Silverberg SG, Makowski EL, Roche WD. 1977. Endometrial carcinoma in women under 40 years of age: comparison of cases in oral contraceptive users and non-users. Cancer 39:592-598.
267. Smith EM, Sowers MF, Burns TL. 1984. Effects of smoking on the development of female reproductive cancers. J Natl Cancer Inst 73:371-376.
268. Soler M, Chatenoud L, Negri E, Parazzini F, Franceschi S, La Vecchia C. 1999. Hypertension and hormone-related neoplasms in women. Hypertension 34:320-325.
269. Spengler RF, Clarke EA, Woolever A, Newman AM, Osborn RW. 1981. Exogenous estrogens and endometrial cancer: A case-control study and assessment of potential bias. Am J Epidemiol 114:497-506.
270. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. 1996. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART Study). JAMA 276:1397-1403.
271. Staland B. 1985. Continuous treatment with a combination of estrogen and gestagen-a way of avoiding endometrial stimulation. Clinical experiences with Kliogest. Acta Obstet Gynecol Scand Suppl 130:29-35.
272. Stampfer M, Colgitz G, Willet W, Rosner B, Hennekens C, Speizer F. 1986. A prospective study of exogenous hormones and risk of endometrial cancer (Abstract). Am J Epidemiol 124:520.
273. Standeven M, Criqui MH, Klauber MR, Gabriel S, Barrett-Connor E. 1986. Correlates of change in postmenopausal estrogen use in a population-based study. Am J Epidemiol 124:268-274.
274. Stanford JL, Brinton LA, Berman ML, et al. 1993. Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 54:243-248.
275. State of California, Department of Health. 1978. Uterine Cancer Incidence. Vol. V, No. 1. Sacramento, California.
276. Stavraky KM, Collins JA, Donner A, Wells GA. 1981. A comparison of estrogen use by women with endometrial cancer, gynecologic disorders, and other illnesses. Am J Obstet Gynecol 141:547-555.
277. Stockwell HG, Lyman GH. 1987. Cigarette smoking and the risk of female reproductive cancer. Am J Obstet Gynecol 157:35-40.
278. Sturdee DW, Wade-Evans T, Paterson ME, Thom M, Studd JW. 1978. Relations between bleeding pattern, endometrial histology, and oestrogen treatment in menopausal women. Br Med J 1:1575-1577.
279. Sturgeon SR, Brinton LA, Berman ML, et al. 1993. Past and present physical activity and endometrial cancer risk. Br J Cancer 68:584-589.
280. Sturgeon SR, Brinton LA, Berman ML, et al. 1997. Intrauterine device use and endometrial cancer risk. Int J Epidemiol 26:496-500.
281. Sturgeon SR, Brock JW, Potischman N, et al. 1998. Serum concentrations of organochlorine compounds and endometrial cancer risk (United States). Cancer Causes Control 9:417-424.
282. Swanson CA, Wilbanks GD, Twiggs LB, et al. 1993. Moderate alcohol consumption and the risk of endometrial cancer. Epidemiol 4:530-536.
283. Szekely DR, Weiss NS, Schweid AI. 1978. Incidence of endometrial carcinoma in King County, Washington: a standardized histologic review. J Natl Cancer Inst 60:985-989.
284. Terry P, Baron JA, Weiderpass E, Yuen J, Lichtenstein P, Nyren O. 1999. Lifestyle and endometrial cancer risk: a cohort study from the Swedish Twin Registry. Int J Cancer 82:38-42.
285. Terry P, Vainio H, Wolk A, Weiderpass E. 2002a. Dietary factors in relation to endometrial cancer: a nationwide case-control study in Sweden. Nutr Cancer 42:25-32.
286. Terry PD, Miller AB, Rohan TE. 2002b. A prospective cohort study of cigarette smoking and the risk of endometrial cancer. Br J Cancer 86:1430-1435.
287. The Centers for Disease Control, Cancer and Steroid Hormone Study. 1983. Oral contraceptive use and the risk of endometrial cancer. JAMA 249:1600-1604.
288. The Centers for Disease Control, Cancer and Steroid Hormone Study. 1987. Combination oral contraceptive use and the risk of endometrial cancer. JAMA 257:796-800.
289. Thom MH, White PJ, Williams RM, et al. 1979. Prevention and treatment of endometrial disease in climacteric women receiving oestrogen therapy. Lancet 2:455-457.
290. Tornberg SA, Carstensen JM. 1994. Relationship between Quetelet's index and cancer of breast and female genital tract in 47,000 women followed for 25 years. Br J Cancer 69:358-361.
291. Tyler CW, Webster LA, Ory HW, Rubin GL. 1985. Endometrial cancer: how does cigarette smoking influence the risk of women under age 55 years having this tumor? Am J Obstet Gynecol 151:899-905.
292. Tzonou A, Lipworth L, Kalandidi A, et al. 1996. Dietary factors and the risk of endometrial cancer: a case-control study in Greece. Br J Cancer 73:1284-1290.
293. U.S. Department of Health and Human Services. 1981. Hysterectomy in women aged 15-44, United States, 1970-1978. MMWR Morb Mortal Wkly Rep 30:173-176.
294. Venn A, Watson L, Bruinsma F, Giles G, Healy D. 1999. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 354:1586-1590.
295. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. 1995. Breast and ovarian cancer incidence after infertility and in vitro fertilization. Lancet 346:995-1000.
296. Vessey MP, Painter R. 1995. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer 71:1340-1342.
297. Villard L, Murphy M. 1990. Endometrial cancer trends in England and Wales: a possible protective effect of oral contraceptives. Int J Epidemiol 19:255-258.
298. Voigt LF, Deng Q, Weiss NS. 1994. Recency, duration, and progestin content of oral contraceptives in relation to the incidence of endometrial cancer (Washington, USA). Cancer, Causes & Control 5:227-233.
299. Voigt LF, Weiss NS, Chu J, Daling JR, McKnight B, Van Belle G. 1991. Progestagen supplementation of exogenous oestrogens and risk of endometrial cancer. Lancet 338:274-277.
300. Waterhouse J, Muri C, Correa P, Powell J. 1976. Cancer Incidence in Five Continents, Vol. 3. IARC, Lyon, France.
301. Waterhouse J, Muri C, Shanmugaratnam K, Powell J. 1982. Cancer Incidence in Five Continents, Vol. 4. IARC, Lyon, France.
302. Webster LA, Weiss NS, the Cancer and Steroid Hormone Study Group. 1989. Alcoholic beverage consumption and the risk of endometrial cancer. Int J Epidemiol 18:786-791.
303. Weiderpass E, Adami HO, Baron JA, et al. 1999a. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91:1131-1137.
304. Weiderpass E, Adami HO, Baron JA, Magnusson C, Lindgren A, Persson I. 1999b. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control 10:277-284.
305. Weiderpass E, Adami HO, Baron JA, et al. 2000a. Organochlorines and endometrial cancer risk. Cancer Epidemiol Biomarkers Prev 9:487-493.
306. Weiderpass E, Baron JA. 2001. Cigarette smoking, alcohol consumption, and endometrial cancer risk: a population-based study in Sweden. Cancer Causes Control 12:239-247.
307. Weiderpass E, Baron JA, Adami HO, et al. 1999c. Low-potency oestrogen and risk of endometrial cancer: a case-control study. Lancet 353:1824-1828.
308. Weiderpass E, Gridley G, Persson I, Nyren O, Ekbom A, Adami H-O. 1997. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 71:360-363.
309. Weiderpass E, Persson I, Adami HO, Magnusson C, Lindgren A, Baron JA. 2000b. Body size in different periods of life, diabetes mellitus, hypertension, and risk of postmenopausal endometrial cancer (Sweden). Cancer Causes Control 11:185-192.
310. Weiderpass E, Persson I, Melhus H, Wedren S, Kindmark A, Baron JA. 2000c. Estrogen receptor alpha gene polymorphisms and endometrial cancer risk. Carcinogenesis 21:623-627.
311. Weir HK, Sloan M, Kreiger N. 1994. The relationship between cigarette smoking and the risk of endometrial neoplasms. Int J Epidemiol 23:261-266.
312. Weiss NS. 1978a. Assessing the risks from menopausal estrogen use: what can we learn from trends in mortality from uterine cancer. J Chron Dis 31:705-708.
313. Weiss NS. 1978b. Noncontraceptive estrogens and abnormalities of endometrial proliferation. Ann Intern Med 88:410-412.
314. Weiss NS, Farewall VT, Szekely DR, English DR, Kiviat N. 1980. Oestrogens and endometrial cancer: effect of other risk factors on the association. Maturitas 2:185-190.
315. Weiss NS, Sayvetz TA. 1980. Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302:551-554.
316. Weiss NS, Szekely DR, Austin DF. 1976. Increasing incidence of endometrial cancer in the United States. N Engl J Med 294:1259-1262.
317. Weiss NS, Szekely DR, English DR, Schweid AI. 1979. Endometrial cancer in relation to patterns of menopausal estrogen use. JAMA 242:261-264.
318. WHI Writing Group. 2002. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
319. Whitehead MI, King RJ, McQueen J, Campbell S. 1979. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestogen therapy. J R Soc Med 72:322-327.
320. Whitehead MI, McQueen J, Beard RJ, Minardi J, Campbell S. 1977. The effects of cyclical oestrogen therapy and sequential oestrogen/progestogen therapy on the endometrium of postmenopausal women. Acta Obstet Gynecol Scand Suppl 91-101.
321. WHO Collaborative Study of Neoplasia and Steroid Contraceptives. 1991. Depot medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. Int J Cancer 49:186-190.
322. Wideroff L, Gridley G, Mellemkjaer L, et al. 1997. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 89:1360-1365.
323. Willett W, Stampfer MJ, Bain C, et al. 1983. Cigarette smoking, relative weight, and menopause. Am J Epidemiol 117:651-658.
324. Williams AR, Weiss NS, Ure CL, Ballard J, Daling JR. 1982. Effect of weight, smoking, and estrogen use on the risk of hip and forearm fractures in postmenopausal women. Obstet Gynecol 60:695-699.
325. Woodruff JD, Pickar JH, and the Menopause Study Group. 1994. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 170:1213-1223.
326. Writing Group for the PEPI Trial. 1995. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 273:199-208.
327. Wynder EL, Escher GC, Mantel N. 1966. An epidemiological investigation of cancer of the endometrium. Cancer 19:489-520.
328. Wysowski DK, Golden L, Burke L. 1995. Use of menopausal estrogens and medroxyprogesterone in the United States, 1982-1992. Obstet Gynecol 85:6-10.
329. Yaron M, Levy T, Chetrit A, et al. 2001. The polymorphic CAG repeat in the androgen receptor gene in Jewish Israeli women with endometrial carcinoma. Cancer 92:1190-1194.
330. Yen SS. 1980. The polycystic ovary syndrome. Clin Endocrinol 12:177-207.
331. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. 2001. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 84:975-981.
332. Zelmanowicz A, Hildesheim A, Sherman ME, et al. 1998. Evidence for a common etiology for endometrial carcinomas and malignant mixed mullerian tumors. Gynecol Oncol 69:253-257.
333. Zheng W, Kushi LH, Potter JD, et al. 1995. Dietary intake of energy and animal foods and endometrial cancer incidence. The Iowa women's health study. Am J Epidemiol 142:388-394.
334. Zheng W, Shu XO, McLaughlin JK, Chow WH, Gao YT, Blot WJ. 1993. Occupational physical activity and the incidence of cancer of the breast, corpus uteri, and ovary in Shanghai. Cancer 71:3620-3624.
335. Ziel HK, Finkle WD. 1975. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 293:1167-1170.